BAYER AG NA O.N. overview

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing PR Newswire REHOVOT, Israel, March 19, 2024 REHOVOT, Israel , March 19, 2024 /PRNewswire/ -- Lavie Bio Ltd ., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced today that it is extending its joint validation trials for...

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution PR Newswire REHOVOT, Israel, Feb. 21, 2024 The collaboration will tap into the potential of artificial intelligence (AI) to design and optimize crop protection chemistry, developing a novel sustainable Mode-of-Action (MoA) broad-spectrum herbicide for farmers REHOVOT, Israel , Feb. 21, 2024 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel...

EQS-Ad-hoc: Bayer Aktiengesellschaft / Key word(s): Dividend Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt 19-Feb-2024 / 17:23 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Leverkusen, February 19, 2024 – Bayer AG plans to amend its dividend policy to pay out the legally required...

Bayer Commits to Veeva Vault CRM and Veeva OpenData Globally PR Newswire PLEASANTON, Calif., Nov. 27, 2023 Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data PLEASANTON, Calif. , Nov. 27, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Bayer will be among the first top 20 biopharmas to move to Veeva Vault CRM worldwide, while also standardizing global customer data with Veeva OpenData . As...

EQS-Ad-hoc: Bayer Aktiengesellschaft / Key word(s): Study results Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy 19-Nov-2023 / 23:47 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Leverkusen/Berlin, November 19, 2023 – OCEANIC-AF, a phase III study investigating asundexian compared...

NORTHAMPTON, MA / ACCESSWIRE / August 29, 2023 / Bayer - As climate change quickens, societal expectations increase and the threat of resistance grows, new crop protection solutions are imperative. Advances in the life sciences and data-driven technologies hold the key to expanding our pipeline and unlocking powerful new possibilities for agriculture. Listen to farmers - no matter where they are in the world - protecting their crops until harvest from damaging insects, diseases, and weeds is...

NORTHAMPTON, MA / ACCESSWIRE / August 24, 2023 / Bayer When it comes to raising crops, protecting them through harvest is often the toughest part of the job. With each changing season, day, hour and even second, you're faced with a number of threats ranging from weeds, disease and pests - couple these with climate change, regulatory pressures, and current supply chain issues, and you've got as much potential for stress as you do for success. That's exactly why we're innovating crop protection...

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand’s extensive experience, connections, and judgement to guide Coya’s strategic discussions and development programs. “I am delighted to join...